

Product datasheet for **TL314628V**

Argininosuccinate Lyase (ASL) Human shRNA Lentiviral Particle (Locus ID 435)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Argininosuccinate Lyase (ASL) Human shRNA Lentiviral Particle (Locus ID 435)
Locus ID:	435
Synonyms:	ASAL
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ASL - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	<u>NM_000048</u> , <u>NM_001024943</u> , <u>NM_001024944</u> , <u>NM_001024946</u> , <u>NM_001024943.1</u> , <u>NM_000048.1</u> , <u>NM_000048.2</u> , <u>NM_000048.3</u> , <u>NM_001024944.1</u> , <u>NM_001024946.1</u> , <u>BC008195</u> , <u>BC008195.1</u> , <u>BC033146</u> , <u>NM_001024946.2</u> , <u>NM_001024944.2</u> , <u>NM_001024943.2</u> , <u>NM_000048.4</u>
UniProt ID:	<u>P04424</u>
Summary:	This gene encodes a member of the lyase 1 family. The encoded protein forms a cytosolic homotetramer and primarily catalyzes the reversible hydrolytic cleavage of argininosuccinate into arginine and fumarate, an essential step in the liver in detoxifying ammonia via the urea cycle. Mutations in this gene result in the autosomal recessive disorder argininosuccinic aciduria, or argininosuccinic acid lyase deficiency. A nontranscribed pseudogene is also located on the long arm of chromosome 22. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .


[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).